IMPAACT 2010 Update: Comparable Safety and Efficacy With DTG + FTC/TAF or FTC/TDF vs EFV/FTC/TDF at 50 Wks Postpartum Following Initiation in Pregnancy

March 6-10, 2021; Virtual

In this randomized noninferiority trial, the overall safety and efficacy of DTG plus FTC/TAF or FTC/TDF was generally similar to EFV/FTC/TDF when initiated during pregnancy, but in post hoc analyses, infant mortality, virologic failure at ≥ 24 weeks, and maternal weight loss were all higher with EFV/FTC/TDF vs DTG-based regimens.

Format: Microsoft PowerPoint (.ppt)
File Size: 176 KB
Released: March 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Expert review of interventions to link HIV diagnosis to successful treatment, from Clinical Care Options (CCO)

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD Released: August 18, 2022

Learn from Dr Jonathan Appelbaum about medical challenges faced by aging people with HIV, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Released: August 17, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS David A. Wohl, MD Released: August 17, 2022

Babafemi Taiwo, MBBS: barriers to HIV testing and opportunities for increasing rates of diagnosis, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: August 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings